- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01940510
A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802
1. november 2016 oppdatert av: Hoffmann-La Roche
An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Rifampin, a Potent Cytochrome P450 3A Inducer, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects
This single center, open-label, 3-period, fixed-sequence study will evaluate the effect of multiple oral doses of rifampin on the pharmacokinetics of a single oral dose of RO5424802 in healthy volunteers.
Subjects will receive a single dose of RO5424802 on Days 1 and 17 and rifampin daily from Days 8 to Day 20.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
24
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Texas
-
Austin, Texas, Forente stater, 78744
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 55 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Healthy male and female volunteers, 18 to 55 years of age inclusive. Healthy status will be defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, and a complete physical examination
- Body mass index (BMI) between 18 to 32 kg/m2 inclusive
- Nonsmoking subjects and former smoking subjects (who have not smoked for the past six months before first dosing)
- Female subjects must be surgically sterile or postmenopausal for the past year
- Male subjects and their partners of childbearing potential must be willing to use two effective methods of contraception, one of which must be a barrier method (e.g., condom) during the study and for 90 days after the last drug administration
Exclusion Criteria:
- Women of childbearing potential, pregnant or lactating women, or males with female partners who are pregnant or lactating
- Positive urine test for drugs of abuse, alcohol, or cotinine test at screening or prior to admission to the study unit
- Suspicion of regular consumption of drug(s) of abuse including marijuana
- Current smokers or subjects who have discontinued smoking less than six months prior to first dosing
- History (within three months of Screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol). Alcohol consumption will be prohibited 72 hours prior to entry in the clinical site center and throughout the entire study (including the washout period) until discharge
- Positive for hepatitis B, hepatitis C, or HIV infection
- Participation in an investigational drug or device study within 45 days or 5 half-lives (whichever time period is longer) or 6 months for biologic therapies prior to first dosing
- Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, absorption, distribution, metabolism or excretion of study medication, or that would, in the opinion of the PI, pose an unacceptable risk to the subject in this study
- History of hypersensitivity to any of the additives in the RO5424802 formulation (lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose, sodium lauryl sulphate, magnesium stearate)
- Any history of hypersensitivity to or contraindication to the use of rifampin or other rifamycins or history of severe drug-related allergic reactions or hepatoxicity
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Sunne fag
|
Single dose without (Day 1) and with (Day 17) co-administration of rifampin
Multiple doses Days 8-16 and Days 17-20
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf]) of Alectinib
Tidsramme: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
AUC(0-inf) is the area under the alectinib plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
AUC is a measure of the plasma concentration of a drug over time.
AUC(0-inf) is presented in nanogram times (*) hour per milliliter (ng*hour/mL).
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Maximum Observed Plasma Concentration (Cmax) of Alectinib
Tidsramme: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Cmax is the maximum observed alectinib plasma concentration, presented in nanogram per milliliter (ng/mL).
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
AUC(0-inf) of RO5468924
Tidsramme: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
AUC(0-inf) is the area under the RO5468924 (the major pharmacologically active metabolite of alectinib) plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
AUC is a measure of the plasma concentration of the drug over time.
AUC(0-inf) is presented in ng*hour/mL.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Cmax of RO5468924
Tidsramme: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Cmax is the maximum observed RO5468924 (the major pharmacologically active metabolite of alectinib) plasma concentration, presented in ng/mL.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUC(0-inf)
Tidsramme: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
AUC(0-inf) is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
AUC is a measure of the plasma concentration of the alectinib and RO5468924 (major pharmacologically active metabolite of alectinib) over time.
The molecular weight adjusted M/P ratio (RO5468924/alectinib) for AUC(0-inf) is presented.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for Cmax
Tidsramme: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Cmax is the maximum observed plasma concentration of the alectinib and RO5468924 (major pharmacologically active metabolite of alectinib).
The molecular weight adjusted M/P ratio (RO5468924/alectinib) for Cmax is presented.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-last]) of Alectinib and RO5468924
Tidsramme: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
AUC(0-last) is the area under the alectinib and RO5468924 (major pharmacologically active metabolite of alectinib) plasma concentration time-curve from time zero to the last measured concentration.
AUC is a measure of the plasma concentration of a drug over time.
AUC(0-last) is presented in ng*hour/mL.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alectinib and RO5468924
Tidsramme: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
The Tmax is the time from alectinib administration to reach Cmax for alectinib and RO5468924 (the major pharmacologically active metabolite of alectinib).
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Plasma Terminal Half-Life (t1/2) of Alectinib and RO5468924
Tidsramme: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Plasma terminal half-life is the time measured during drug elimination phase for the plasma drug concentration to decrease by one half.
RO5468924 is the major pharmacologically active metabolite of alectinib.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Apparent Oral Clearance (CL/F) of Alectinib
Tidsramme: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Apparent Volume of Distribution (Vz/F) of Alectinib
Tidsramme: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction of drug absorbed.
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Total Molar Concentration of Alectinib and RO5468924 as Derived by AUC(0-inf)
Tidsramme: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
AUC(0-inf) is the area under the alectinib + RO5468924 (major pharmacologically active metabolite of alectinib) molar plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-inf).
AUC is a measure of the molar plasma concentration of the alectinib + RO5468924 over time.
AUC(0-inf) is presented in nanomoles times (*) hour per liter (nmol*hour/L).
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Total Molar Concentration of Alectinib and RO5468924 as Derived by Cmax
Tidsramme: Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Cmax is the maximum observed molar plasma concentration for alectinib + RO5468924 (major pharmacologically active metabolite of alectinib).
Cmax is presented in nanomoles per liter (nmol/L).
|
Predose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours post alectinib-dose in each intervention period
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. oktober 2013
Primær fullføring (Faktiske)
1. oktober 2013
Studiet fullført (Faktiske)
1. oktober 2013
Datoer for studieregistrering
Først innsendt
9. september 2013
Først innsendt som oppfylte QC-kriteriene
9. september 2013
Først lagt ut (Anslag)
12. september 2013
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
21. desember 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
1. november 2016
Sist bekreftet
1. november 2016
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Nukleinsyresyntesehemmere
- Enzymhemmere
- Antibakterielle midler
- Leprostatiske midler
- Cytokrom P-450 enzymindusere
- Cytokrom P-450 CYP3A indusere
- Antituberkulære midler
- Antibiotika, Antituberkulær
- Cytokrom P-450 CYP2B6 indusere
- Cytokrom P-450 CYP2C8 indusere
- Cytokrom P-450 CYP2C19 indusere
- Cytokrom P-450 CYP2C9 indusere
- Rifampin
Andre studie-ID-numre
- NP29042
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Frivillig frisk
-
Universidade do PortoFundação para a Ciência e a TecnologiaRekrutteringHealthy People-programmerPortugal
-
VA Office of Research and DevelopmentFullført
-
Universidad Católica del MauleFullført
-
University of MiamiJames and Esther King Biomedical Research ProgramAvsluttetHealthy Lifetime Ikke-røykereForente stater
-
Fundació Institut de Recerca de l'Hospital de la...FullførtHealthy People-programmerSpania
-
University of LeicesterNational Institute for Health Research, United KingdomFullførtPasienter med hjertesvikt og bevart ejeksjonsfraksjon - HFpEF | Pasienter med hjertesvikt med redusert ejeksjonsfraksjon - HFrEF | Healthy Controls Group - alders- og kjønnsmatchet
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesAvsluttetParkinsons sykdom | Healthy Controls Group - alders- og kjønnsmatchetFrankrike
Kliniske studier på RO5424802
-
Hoffmann-La RocheFullført
-
Hoffmann-La RocheFullførtIkke-småcellet lungekreftForente stater, Canada
-
Hoffmann-La RocheAktiv, ikke rekrutterendeIkke-småcellet lungekreftForente stater, Korea, Republikken, Canada, Taiwan, Australia, Frankrike, Hong Kong, Italia, Portugal, Spania, Storbritannia, Brasil, Polen, Guatemala, Singapore, Thailand, Serbia, Ukraina, Bosnia og Herzegovina, Chile, Kina, Costa... og mer
-
Hoffmann-La RocheAktiv, ikke rekrutterendeAnaplastisk lymfom kinasepositiv ikke-småcellet lungekreftKina, Korea, Republikken, Thailand
-
Hoffmann-La RocheFullført
-
Hoffmann-La RocheFullførtFrivillig friskForente stater
-
Hoffmann-La RocheAktiv, ikke rekrutterendeKarsinom, ikke-småcellet lungeForente stater, Ungarn, Australia, Taiwan, Kina, Danmark, Italia, Spania, Tyrkia, Japan, Frankrike, Korea, Republikken, Tyskland, Polen, Thailand, Egypt, Den russiske føderasjonen, Østerrike, Ukraina, Storbritannia, Romania, Kasakhstan og mer
-
Hoffmann-La RocheRekrutteringIkke-småcellet lungekreftCanada, Belgia, Korea, Republikken, Forente stater, Frankrike, Brasil, Kina, New Zealand, Israel, Spania, Argentina, Serbia, Mexico, Italia, Japan, Peru, Tyrkia, Taiwan, Costa Rica, Thailand, Australia, Tyskland, Hong Kong, Nederland, Polen, Den russiske føderasjonen og mer
-
National Cancer Institute (NCI)NRG OncologyAktiv, ikke rekrutterendeStage IVA lungekreft AJCC v8 | Stage IVB lungekreft AJCC v8 | Stadium IV lungekreft AJCC v8 | Lunge ikke-plateepitel, ikke-småcellet karsinomForente stater
-
Genentech, Inc.FullførtAvansert ikke-opererbar eller metastatisk solid malignitetForente stater